FDA Announces Approval of Second Rx Drug in New Class of Cholesterol-Lowering Medications
On Thursday, FDA approved Amgen's Repatha, the second medication to be approved in a new class of cholesterol-lowering drugs known as PCSK9 inhibitors. FDA has approved Repatha for two groups of patients who are unable to control cholesterol levels with existing treatments: those with very high LDL cholesterol because of an inherited condition; and those with a history of heart attack, stroke or other cardiovascular issues.
- "New Drug Could Dramatically Reduce Cholesterol" (Szabo, USA Today, 8/28).
- "Amgen Wins Approval for Second Biotech Cholesterol Drug" (AP/Modern Healthcare, 8/27).